Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.

Guillermo Garcia-Manero,Valeria Santini,Antonio Almeida,Uwe Platzbecker,Anna Jonasova,Lewis R. Silverman,Jose F Falantes,Gianluigi Reda,Francesco Buccisano,Pierre Fenaux,Rena Buckstein,María Díez-Campelo,Stephen Larsen,David Valcárcel,Paresh Vyas,Valentina Giai,Esther Oliva,Jake Shortt,Dietger Niederwieser,Moshe Mittelman,Luana Fianchi,Ignazia La Torre,Jianhua Zhong,Eric Laille,Daniel Menezes,Barry S. Skikne,C. L. Beach,Aristoteles Giagounidis

Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.

2021

PURPOSETreatment options are limited for patients with lower-risk myelodysplastic syndromes (LR-MDS). This phase III, placebo-controlled trial evaluated CC-486 (oral azacitidine), a hypomethylating...

Keywords:

Internal medicine
Oral Azacitidine
Lower risk
MEDLINE
Placebo-controlled study
in patient
Myelodysplastic syndromes
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations